<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004402</url>
  </required_header>
  <id_info>
    <org_study_id>199/13284</org_study_id>
    <secondary_id>MUSC-FDR000768</secondary_id>
    <nct_id>NCT00004402</nct_id>
  </id_info>
  <brief_title>Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the rate of treatment failure in osteopetrosis patients receiving&#xD;
      interferon gamma in combination with calcitriol to the rate of treatment failure in patients&#xD;
      receiving calcitriol alone.&#xD;
&#xD;
      II. Compare the number of adverse events or clinical manifestations of disease progression&#xD;
      occurring in these patients.&#xD;
&#xD;
      III. Assess the effects of interferon gamma on hematopoiesis, cranial nerve function, and&#xD;
      rate of infection in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, placebo controlled, open label study. Patients are&#xD;
      randomized to one of two arms (interferon gamma in combination with calcitriol or calcitriol&#xD;
      alone).&#xD;
&#xD;
      Arm I: Patients receive calcitriol once daily. Interferon gamma is administered by&#xD;
      subcutaneous injection three times a week.&#xD;
&#xD;
      Arm II: Patients receive calcitriol once daily. Patients may continue treatment in the&#xD;
      absence of toxicity and disease progression. If disease progression is diagnosed in the&#xD;
      control group, patients will then receive interferon gamma in combination with calcitriol.&#xD;
&#xD;
      Patients are followed every 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <completion_date>June 2000</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Osteopetrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcitriol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon gamma</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Biopsy and x-ray confirmed primary osteopetrosis&#xD;
&#xD;
          -  Presence of anemia and/or cranial nerve compression&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Biologic therapy: No prior/concurrent bone marrow transplantation No prior interferon&#xD;
             gamma No other investigational biologic agents&#xD;
&#xD;
          -  Chemotherapy: No prior/concurrent chemotherapeutic agents for bone marrow&#xD;
             transplantation&#xD;
&#xD;
          -  Endocrine therapy: Prior/concurrent corticosteroid as supportive therapy allowed&#xD;
&#xD;
          -  Radiotherapy: Not specified&#xD;
&#xD;
          -  Surgery: At least 5 days since major surgery&#xD;
&#xD;
          -  Other: Prior/concurrent calcitriol as supportive therapy allowed Prior/concurrent&#xD;
             transfusion as supportive therapy allowed Prior/concurrent dietary therapy allowed&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 2 months to 10 years&#xD;
&#xD;
          -  Performance status: Not specified&#xD;
&#xD;
          -  Life expectancy: At least 6 months&#xD;
&#xD;
          -  Hematopoietic: Not specified&#xD;
&#xD;
          -  Hepatic: Bilirubin less than 2 mg/dL&#xD;
&#xD;
          -  Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  Pulmonary: No uncorrected airway obstruction&#xD;
&#xD;
          -  Other: No active infection requiring intravenous antibiotics No known seizure disorder&#xD;
             not related to hypocalcemia No uncorrected hydrocephalus No MRI evidence of cerebral&#xD;
             atrophy Must maintain or gain body weight No sleep apnea No thrombocytopenia No&#xD;
             massive splenomegaly&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L. Lyndon Key, Jr.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <verification_date>January 2001</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>osteopetrosis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

